Clinical trials: Monocytes
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of tipifarnib in treating older patients who have previously untreated acute myeloid…
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6)
- Trial name
- NCT00027872
- Testing
- tipifarnib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia
RATIONALE: Studying blood samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01421875
- Testing
- DNA methylation analysis, RNA analysis, gene expression analysis
- Volunteers
- 257 people
- Sponsor
- Eastern Cooperative Oncology Group
Immunosuppression
Monitoring of Corticosteroids Induced Immunosuppression Using Monocyte Human Leukocyte Antigen-DR (mHLA-DR).
Corticotherapy is widely used in auto-immune diseases. If induced immunosuppression by corticosteroids is well admitted, it's currently not possible to determine individual risk of infection.
- Trial name
- HLA-DR (NCT04360772)
- Testing
- mHLA-DR
- Sponsor
- Hospices Civils de Lyon
Leukemia
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission
RATIONALE: Vaccines made from dendritic cells may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy and to see how well it works in…
- Trial name
- NCT00963521
- Testing
- therapeutic autologous dendritic cells
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Institut Paoli-Calmettes
HER2-positive
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
This is a first-in-human open-label study to evaluate the safety and tolerability, and manufacturing feasibility of anti-HER2 CAR-monocytes (CT-0525) in participants with locally advanced (unresectable) or metastatic solid tumors…
- Trial name
- NCT06254807
- Testing
- CT-0525
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Carisma Therapeutics Inc
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia
This phase I trial studies the best dose of azacitidine and to see how well it works with mitoxantrone hydrochloride and etoposide in treating older patients with acute myeloid leukemia that has a lower chance of responding to…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia
- Trial name
- NCT01260714
- Testing
- Azacitidine, Etoposide, Laboratory Biomarker Analysis
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have…
- Trial name
- NCT00006092
- Testing
- Arsenic Trioxide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
This phase II trial is studying how well tipifarnib works in treating older patients with acute myeloid leukemia. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Trial name
- NCT01361464
- Testing
- Tipifarnib, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
Phase I trial to study the effectiveness of SB-715992 in treating patients who have acute leukemia, chronic myelogenous leukemia, or advanced myelodysplastic syndromes.
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00098826
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006084
- Testing
- lintuzumab
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
COVID 19, Lymphopenia Due to COVID-19
The Effect of Monocyte Values Accompanied by Lymphopenia on the Prognosis of Patients Diagnosed With COVID-19
Recent studies have shown that lymphopenia with cytokine storm syndrome is frequently found in COVID-19 patients. These features may suggest that the modified immune system plays a key role in determining disease progression.
- Conditions
- COVID 19, Lymphopenia Due to COVID-19, Monocyte
- Trial name
- NCT06968156
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Dysmetabolic Iron Overload Syndrome, Metabolic Syndrome X
MEPHISTO (Macrophage Phenotype In Metabolic Syndrome With Iron Overload)
Dysmetabolic iron overload syndrome (DIOS), is a frequent hepatic iron overload associated with metabolic syndrome. We hypothesize that this mild iron overload can induce a increased macrophagic polarization towards inflammatory…
- Trial name
- MEPHISTO (NCT02066012)
- Testing
- dysmetabolic iron overload syndrome
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Multiple Sclerosis
Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
In this study we wish to test the hypothesis that continuous Gilenya treatment alters immune homeostasis in favor of an anti-inflammatory type II monocyte and macrophage (M2) phenotype in the circulation of patients with…
- Trial name
- NCT02225977
- Testing
- Gilenya
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Southern California
Leukemia, Neutropenia
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in the bone marrow or…
- Trial name
- NCT00002719
- Testing
- filgrastim, amsacrine, carmustine
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Coronary Syndrome, ACS (Acute Coronary Syndrome)
Evaluation of Remnant Cholesterol Levels and Monocyte-to-HDL-cholesterol Ratio as Predictors of Coronary Artery Disease Severity in Patients With Acute Coronary Syndrome
1. Evaluation of serum level of remnant cholesterol and monocyte/HDL ratio as predictors of severity of coronary artery disease in patients with acute coronary syndrome. 2.
- Conditions
- Acute Coronary Syndrome, ACS (Acute Coronary Syndrome), Monocyte to HDL Cholesterol Ratio, STEMI
- Trial name
- NCT06757777
- Volunteers
- 54 people
- Sponsor
- Assiut University
Regional Anesthesia, General Anesthesia
Monocyte Subsets Altered by Anesthesia
The impact of different anesthetic techniques on the immune system remains unclear. Aim of this ex vivo / in vitro study was to determine the effects of general and neuraxial anesthesia on monocyte subset alteration and the…
- Conditions
- Regional Anesthesia, General Anesthesia, Immune Function
- Trial name
- NCT03431532
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital, Saarland
Leukemia
S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01059734
- Testing
- DNA analysis, RNA analysis, mutation analysis
- Volunteers
- 357 people
- Sponsor
- SWOG Cancer Research Network
Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the MEK inhibitor MEK162 to see if it is safe in patients when combined with idarubicin and cytarabine.
- Conditions
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2)
- Trial name
- NCT02049801
- Testing
- MEK inhibitor MEK162, idarubicin, cytarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bruno C. Medeiros
Leukemia
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as cytarabine and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112554
- Testing
- cytarabine, laromustine
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 420 people
- Sponsor
- Vion Pharmaceuticals
Intestinal Manipulation
Study on the Effect of Surgical Intestinal Manipulation
The aim of this study is to study the impact of brain death and surgical small bowel manipulation on the release of different types of monocytes.
- Trial name
- IMMO (NCT02189512)
- Testing
- blood sampling
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven